Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Lilly intends to submit the drug to regulators by the end of 2025, positioning it as the first oral GLP-1 receptor agonist approved specifically for obesity
No evidence of cardiac, hepatic, or renal toxicity, changes in serum lipids, or clinically relevant changes in laboratory parameters, vital signs, electrocardiograms, or abnormal findings upon physical examinations have been observed
The Medicines and Healthcare products Regulatory Agency (MHRA) continues to monitor the safety profile of these medications
The dose may be increased again to 14 mg once daily if additional glycemic control is needed after 30 days of treatment with the 7-mg dose
Two analyses were conducted using propensity-score matching for baseline covariates
This effect can reduce glycemic excursions, which are often difficult to manage with insulin alone
